跳转至内容
Merck
  • Decreased bone marrow stromal cells activity involves in unilateral anterior crossbite-induced early subchondral bone loss of temporomandibular joints.

Decreased bone marrow stromal cells activity involves in unilateral anterior crossbite-induced early subchondral bone loss of temporomandibular joints.

Archives of oral biology (2014-06-16)
Ting Yang, Jing Zhang, Yukun Cao, Mian Zhang, Lei Jing, Kai Jiao, Shibin Yu, Meiqing Wang
摘要

Subchondral bone loss in mandibular condyles was reported to be induced by experimentally created unilateral anterior crossbite (UAC) which altered the occlusal load distribution and hereafter the temporomandibular joint (TMJ) remodelling process. However, the initial cellular responses are poorly understood. In the present study, changes in osteoblast and osteoclast activities in TMJ subchondral bone were investigated using the rats treated with UAC. Forty rats were randomly divided into UAC and control groups, and sampled at 2 weeks after the operation. Subchondral bone loss was evaluated by micro-CT. Osteoclast and osteoblast activities were analyzed by real-time PCR. The osteoblast differentiation of the locally isolated BMSCs from TMJ subchondral bone was assessed by Alizarin red staining. The migration of BMSCs was detected by transwell assays. Compared with the age-matched controls, TMJ subchondral bone loss was observed in the UAC-treated rats (p<0.05). The osteoblast activity evaluated by real-time PCR and osteoblast number revealed by immunohistochemical staining were reduced in the TMJ subchondral bone of UAC rats (p<0.05), and the capability of proliferation, migration and osteoblast differentiation were all decreased in the locally isolated BMSCs from the UAC group (p<0.05). The present data demonstrated an involvement of reduced BMSCs activity in the initiation of the mandibular subchondral bone loss at the early stage of installation of the aberrant prostheses.

材料
货号
品牌
产品描述

Sigma-Aldrich
地塞米松, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
3-异丁基-1-甲基黄嘌呤, ≥99% (HPLC), powder
Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
碘化丙啶, ≥94.0% (HPLC)
Sigma-Aldrich
3-异丁基-1-甲基黄嘌呤, ≥99%, BioUltra
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
地塞米松, ≥98% (HPLC), powder
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
USP
抗坏血酸, United States Pharmacopeia (USP) Reference Standard
Supelco
L -抗坏血酸, analytical standard
Sigma-Aldrich
L -抗坏血酸, reagent grade
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
地塞米松, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
L -抗坏血酸, FCC, FG
Supelco
维生素C, Pharmaceutical Secondary Standard; Certified Reference Material
USP
地塞米松, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
L -抗坏血酸, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Sigma-Aldrich
碘化丙啶 溶液
Sigma-Aldrich
地塞米松, meets USP testing specifications
Supelco
地塞米松, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
碘化丙啶, ≥94% (HPLC)
Sigma-Aldrich
凝血酶受体激动剂, ≥97% (HPLC)
维生素C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
L -抗坏血酸, tested according to Ph. Eur.
Supelco
L -抗坏血酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland